🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 45 (from laksa121)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa045.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial\')), getAhrefsUnparsedNoserviceFromURL(\'https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial","crawl_time":1761046797,"first_indexed_time":1670700859,"http_code":200,"src_unparsed":"edu,umn!cidrap,www,\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial s443","src_root_hash":"1624480930799954845","history_drop_reason":null,"meta_title":"COVID-19 vaccine for kids under 5 delayed as Pfizer extends trial | CIDRAP","meta_descriptions":[],"attrs_boilerpipe_text":"In a sudden turnabout, Pfizer and BioNTech today announced they were delaying the application process for an emergency use authorization (EUA) for their vaccine for children ages 6 months to 4 years old, and gathering more information on two and three doses of the vaccine. The announcement comes just days before the Food and Drug Administration (FDA) was set to consider the application, and a day after the Centers for Disease Control and Prevention (CDC) had told pediatric vaccine providers to ready themselves for a Feb 21 delivery date of the mRNA vaccine. \"As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial,\" the FDA said in a  statement . \"Based on the agency's preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.” In December, Pfizer released data on two 3-microgram doses of the Pfizer-BioNTech vaccine in children 6 months to 4 years. In children 2 years and older, the reduced doses did not elicit a significant immune response, and the company suggested a third dose may be needed. Today in a statement Pfizer said an ongoing study of a third dose of vaccine administered 2 months after the primary series is \"advancing at a rapid pace,\" and the companies will wait for the three-dose data, which they  expect to have by early April , before applying for the EUA. The FDA meeting scheduled for Feb 15 has been delayed until further notice. Data: Protection drops 4 months after third dose Today in  Morbidity and Mortality Weekly Report,  scientists present new research showing that protection against Omicron hospitalizations and emergency department visits drops significantly by 4 months after a third booster dose but is overall still high. Using data  from a multistate analysis of 241,204 emergency department encounters and 93,408 hospitalizations for COVID-19 from Aug 26, 2021, to Jan 22, 2022, the authors found vaccine effectiveness (VE) during the Omicron-predominant period was 87% against emergency department or urgent care (ED\/UC) visits and 91% against hospitalization during the 2 months following a booster dose of vaccine. VE dropped to 66% and 78% against COVID-19–associated ED\/UC visits and hospitalizations, respectively, at 4 months after a booster dose. The authors said the data mirror what has been seen in Israel. The CDC  COVID Data Tracker  shows that 64.3% of Americans are fully vaccinated against COVID-19, 75.8% have received at least one dose of vaccine, and 42.6% of fully vaccinated Americans have received a booster dose. In related news, the FDA today granted an  EUA to bebtelovimab , Eli Lilly's monoclonal antibody, for the treatment of mild to moderate COVID-19 in adults and pediatric patients. Pediatric patients must be at least 12 years of age. Bebtelovimab is effective against infections caused by the Omicron variant, but it must be administered intravenously. Eli Lilly said yesterday that  600,000 courses of the treatment , worth $720 million, have already been made available for the federal government to distribute. Deaths increase in South The United States reported 147,416 new COVID-19 cases yesterday and 3,179 deaths, according to the Johns Hopkins COVID-19  tracker . The 7-day average of new daily cases is 218,688, with 2,613 daily deaths, according to the  Washington Post tracker . Two-week COVID-19 death counts have more than doubled in Florida, Hawaii, Mississippi, South Carolina, and Virginia, according to an  NBC News  analysis of federal data. Twenty-three states have seen a greater than 25% increase in COVID-19 deaths over the past 2 weeks. UK notes rise in subvariant cases Meanwhile, in its latest  update  on SARS-CoV-2 variants today, the United Kingdom's Health Security Agency (HAS) said the proportion of BA.2 subvariant cases is increasing compared to the original Omicron variant. The rise is occurring against the backdrop of an overall decrease in cases. As of Feb 6, the proportion of BA.2 cases, as indicated by S-gene target positivity on PCR tests, in England is 18.7%, compared with 5.1% Jan 24, which HAS said suggests the growth rate is substantial. Based on limited sequences sampled, there are no confirmed BA.2 reinfections in those infected with the parent Omicron variant. And contact tracing data suggest the average time from symptom onset from a primary case to contacts is about a half day shorter for BA.2 than BA.1, which the HSA said might be contributing to BA.2's increased growth rate. In other global COVID-19 news: Hong Kong again today reported a record high for cases, with  1,323  more reported. Talks are under way with officials in mainland China about ways it could support Hong Kong's overburdened health system during the surge, according to  Reuters . Germany's chancellor said today that the country is  nearing the peak  of its Omicron surge and that officials will begin lifting some restrictions next week, with an eye toward easing all of them in the spring. Australia's top officials yesterday accepted a recommendation from vaccine advisers that people need to receive booster doses to be considered  fully vaccinated . However, it will consider international travelers to be fully vaccinated with a two-dose series. The World Health Organization (WHO) today  announced  that it has qualified its first monoclonal antibody, tocilizumab, an intravenous drug designed to inhibit the inflammatory response known to be high in critically ill COVID-19 patients. The drug is already authorized to treat arthritis in about 120 countries. The drug is expensive and supplies are short, but the WHO said more manufacturers are entering the market, with talks under way with Roche about easing access for low- and middle-income countries. The global total today climbed to 407,446,539 cases, and 5,785,805 people have died from their infections, according to the Johns Hopkins  online dashboard . CIDRAP News Editor Lisa Schnirring contributed to this story.","attrs_markdown":"Menu\n\n- [News](https:\/\/www.cidrap.umn.edu\/)\n- [Topics & ProjectsToggle submenu](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-2)\n  - [Antimicrobial Resistance](https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship)\n  - [COVID-19](https:\/\/www.cidrap.umn.edu\/covid-19)\n  - [Chronic Wasting Disease](https:\/\/www.cidrap.umn.edu\/chronic-wasting-disease)\n  - [Influenza](https:\/\/www.cidrap.umn.edu\/influenza-general)\n  - [Resilient Drug Supply](https:\/\/www.cidrap.umn.edu\/resilient-drug-supply)\n  - [Coronavirus Vaccines Roadmap](https:\/\/www.cidrap.umn.edu\/coronavirus-vaccines-roadmap)\n  - [Influenza Vaccines Roadmap](https:\/\/ivr.cidrap.umn.edu\/ \"(opens in a new window)\")\n  - [Roadmaps for Priority Pathogens](https:\/\/www.cidrap.umn.edu\/roadmap-development)\n  - [Vaccine Integrity Project](https:\/\/www.cidrap.umn.edu\/vaccine-integrity-project)\n  - [CIDRAP Leadership Forum](https:\/\/www.cidrap.umn.edu\/forum \"CIDRAP Leadership Forum\")\n  - .\n  - .\n  - [All Topics A-Z](https:\/\/www.cidrap.umn.edu\/infectious-disease-topics)\n- [PodcastsToggle submenu](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-3)\n  - [Antimicrobial Stewardship](https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship\/superbugs-you)\n  - [Chronic Wasting Disease](https:\/\/www.cidrap.umn.edu\/chronic-wasting-disease\/cwd-pod)\n  - [Osterholm Update](https:\/\/www.cidrap.umn.edu\/osterholm-update)\n- [Newsletters](https:\/\/www.cidrap.umn.edu\/newsletter)\n- [AboutToggle submenu](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-4)\n  - [About CIDRAP](https:\/\/www.cidrap.umn.edu\/about-cidrap)\n  - [CIDRAP in the News](https:\/\/www.cidrap.umn.edu\/cidrap-news)\n  - [Our Staff](https:\/\/www.cidrap.umn.edu\/about-us\/cidrap-staff)\n  - [Our Director](https:\/\/www.cidrap.umn.edu\/michael-t-osterholdm-phd-mph)\n  - [Osterholm in the Press](https:\/\/www.cidrap.umn.edu\/osterholm-quotes)\n  - [Shop Merchandise](https:\/\/www.mnalumnimarket.com\/collections\/cidrap?utm_source=website&utm_medium=website&utm_campaign=CIDRAPdonate&utm_content=CIDRAP \"(opens in a new window)\")\n  - [Contact Us](https:\/\/www.cidrap.umn.edu\/contact-us)\n- [Donate](https:\/\/www.cidrap.umn.edu\/support)\n\n[Skip to main content](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#main-content)\n\n[Main navigation](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#main-nav)\n\n**University of Minnesota**  \nhttp:\/\/twin-cities.umn.edu\/  \n612-625-5000\n\n[Go to the U of M home page](http:\/\/twin-cities.umn.edu\/ \"(opens in a new window)\")\n\n[![Home](https:\/\/www.cidrap.umn.edu\/themes\/custom\/cidrap_theme\/logo-internal.svg)](https:\/\/www.cidrap.umn.edu\/ \"Home\")\n\n## Main navigation\n- [News](https:\/\/www.cidrap.umn.edu\/)\n- - [Antimicrobial Resistance](https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship)\n  - [COVID-19](https:\/\/www.cidrap.umn.edu\/covid-19)\n  - [Chronic Wasting Disease](https:\/\/www.cidrap.umn.edu\/chronic-wasting-disease)\n  - [Influenza](https:\/\/www.cidrap.umn.edu\/influenza-general)\n  - [Resilient Drug Supply](https:\/\/www.cidrap.umn.edu\/resilient-drug-supply)\n  - [All Topics A-Z](https:\/\/www.cidrap.umn.edu\/infectious-disease-topics)\n  - [Coronavirus Vaccines Roadmap](https:\/\/www.cidrap.umn.edu\/coronavirus-vaccines-roadmap)\n  - [Influenza Vaccines Roadmap](https:\/\/ivr.cidrap.umn.edu\/ \"(opens in a new window)\")\n  - [Roadmaps for Priority Pathogens](https:\/\/www.cidrap.umn.edu\/roadmap-development)\n  - [Vaccine Integrity Project](https:\/\/www.cidrap.umn.edu\/vaccine-integrity-project)\n  - [CIDRAP Leadership Forum](https:\/\/www.cidrap.umn.edu\/forum \"CIDRAP Leadership Forum\")\n  - .\n  - .\n  Topics & Projects\n- - [Antimicrobial Stewardship](https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship\/superbugs-you)\n  - [Chronic Wasting Disease](https:\/\/www.cidrap.umn.edu\/chronic-wasting-disease\/cwd-pod)\n  - [Osterholm Update](https:\/\/www.cidrap.umn.edu\/osterholm-update)\n  Podcasts\n- [Newsletters](https:\/\/www.cidrap.umn.edu\/newsletter)\n- - [About CIDRAP](https:\/\/www.cidrap.umn.edu\/about-cidrap)\n  - [CIDRAP in the News](https:\/\/www.cidrap.umn.edu\/cidrap-news)\n  - [Our Staff](https:\/\/www.cidrap.umn.edu\/about-us\/cidrap-staff)\n  - [Our Director](https:\/\/www.cidrap.umn.edu\/michael-t-osterholdm-phd-mph)\n  - [Osterholm in the Press](https:\/\/www.cidrap.umn.edu\/osterholm-quotes)\n  - [Shop Merchandise](https:\/\/www.mnalumnimarket.com\/collections\/cidrap?utm_source=website&utm_medium=website&utm_campaign=CIDRAPdonate&utm_content=CIDRAP \"(opens in a new window)\")\n  - [Contact Us](https:\/\/www.cidrap.umn.edu\/contact-us)\n  About\n\nSearch\n\n- [Support](https:\/\/www.cidrap.umn.edu\/support)\n\n[Menu](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#off-canvas \"Menu\")\n\n# COVID-19 vaccine for kids under 5 delayed as Pfizer extends trial\nStephanie Soucheray \\| News Reporter \\| CIDRAP News\n\nFebruary 11, 2022\n\n[COVID-19](https:\/\/www.cidrap.umn.edu\/covid-19)\n\n![Pfizer COVID vaccine vial drawing into syringe](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/article_detail\/public\/images\/news\/pfizer_vax_vial_with_syringe-us_navy.jpg?itok=D-13YH6B)\n\n![Pfizer COVID vaccine vial drawing into syringe](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/thumbnail\/public\/media\/article\/pfizer_vax_vial_with_syringe-us_navy.jpg?itok=JOb_-X5z)\n\n> US Navy, Brett McMinoway \/ Flickr cc\n\nShare\n\nIn a sudden turnabout, Pfizer and BioNTech today announced they were delaying the application process for an emergency use authorization (EUA) for their vaccine for children ages 6 months to 4 years old, and gathering more information on two and three doses of the vaccine.\n\nThe announcement comes just days before the Food and Drug Administration (FDA) was set to consider the application, and a day after the Centers for Disease Control and Prevention (CDC) had told pediatric vaccine providers to ready themselves for a Feb 21 delivery date of the mRNA vaccine.\n\n\"As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial,\" the FDA said in a [statement](https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-postpones-advisory-committee-meeting-discuss-request-authorization \"(opens in a new window)\"). \"Based on the agency's preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.”\n\nIn December, Pfizer released data on two 3-microgram doses of the Pfizer-BioNTech vaccine in children 6 months to 4 years. In children 2 years and older, the reduced doses did not elicit a significant immune response, and the company suggested a third dose may be needed.\n\nToday in a statement Pfizer said an ongoing study of a third dose of vaccine administered 2 months after the primary series is \"advancing at a rapid pace,\" and the companies will wait for the three-dose data, which they [expect to have by early April](https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-provide-update-rolling-submission \"(opens in a new window)\"), before applying for the EUA.\n\nThe FDA meeting scheduled for Feb 15 has been delayed until further notice.\n\n### Data: Protection drops 4 months after third dose\nToday in *Morbidity and Mortality Weekly Report,* scientists present new research showing that protection against Omicron hospitalizations and emergency department visits drops significantly by 4 months after a third booster dose but is overall still high.\n\n[Using data](https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7107e2.htm \"(opens in a new window)\") from a multistate analysis of 241,204 emergency department encounters and 93,408 hospitalizations for COVID-19 from Aug 26, 2021, to Jan 22, 2022, the authors found vaccine effectiveness (VE) during the Omicron-predominant period was 87% against emergency department or urgent care (ED\/UC) visits and 91% against hospitalization during the 2 months following a booster dose of vaccine.\n\nVE dropped to 66% and 78% against COVID-19–associated ED\/UC visits and hospitalizations, respectively, at 4 months after a booster dose. The authors said the data mirror what has been seen in Israel.\n\nThe CDC [COVID Data Tracker](https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total \"(opens in a new window)\") shows that 64.3% of Americans are fully vaccinated against COVID-19, 75.8% have received at least one dose of vaccine, and 42.6% of fully vaccinated Americans have received a booster dose.\n\nIn related news, the FDA today granted an [EUA to bebtelovimab](https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains \"(opens in a new window)\"), Eli Lilly's monoclonal antibody, for the treatment of mild to moderate COVID-19 in adults and pediatric patients. Pediatric patients must be at least 12 years of age.\n\nBebtelovimab is effective against infections caused by the Omicron variant, but it must be administered intravenously. Eli Lilly said yesterday that [600,000 courses of the treatment](https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-will-supply-600000-doses-bebtelovimab-us-government \"(opens in a new window)\"), worth \\$720 million, have already been made available for the federal government to distribute.\n\n### Deaths increase in South\nThe United States reported 147,416 new COVID-19 cases yesterday and 3,179 deaths, according to the Johns Hopkins COVID-19 [tracker](https:\/\/coronavirus.jhu.edu\/data\/cumulative-cases \"(opens in a new window)\").\n\nThe 7-day average of new daily cases is 218,688, with 2,613 daily deaths, according to the *Washington Post* [tracker](https:\/\/www.washingtonpost.com\/graphics\/2020\/national\/coronavirus-us-cases-deaths\/?itid=hp_pandemic_gfx\/?state=US&indicator=reported_cases \"(opens in a new window)\").\n\nTwo-week COVID-19 death counts have more than doubled in Florida, Hawaii, Mississippi, South Carolina, and Virginia, according to an [NBC News](https:\/\/www.nbcnews.com\/news\/all\/covid-death-hot-spot-map-n1288947 \"(opens in a new window)\") analysis of federal data. Twenty-three states have seen a greater than 25% increase in COVID-19 deaths over the past 2 weeks.\n\n### UK notes rise in subvariant cases\nMeanwhile, in its latest [update](https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1054357\/Technical-Briefing-36-11February2022_v2.pdf \"(opens in a new window)\") on SARS-CoV-2 variants today, the United Kingdom's Health Security Agency (HAS) said the proportion of BA.2 subvariant cases is increasing compared to the original Omicron variant. The rise is occurring against the backdrop of an overall decrease in cases.\n\nAs of Feb 6, the proportion of BA.2 cases, as indicated by S-gene target positivity on PCR tests, in England is 18.7%, compared with 5.1% Jan 24, which HAS said suggests the growth rate is substantial.\n\nBased on limited sequences sampled, there are no confirmed BA.2 reinfections in those infected with the parent Omicron variant. And contact tracing data suggest the average time from symptom onset from a primary case to contacts is about a half day shorter for BA.2 than BA.1, which the HSA said might be contributing to BA.2's increased growth rate.\n\nIn other global COVID-19 news:\n\n- Hong Kong again today reported a record high for cases, with [1,323](https:\/\/www.info.gov.hk\/gia\/general\/202202\/11\/P2022021100675.htm?fontSize=1 \"(opens in a new window)\") more reported. Talks are under way with officials in mainland China about ways it could support Hong Kong's overburdened health system during the surge, according to [Reuters](https:\/\/www.reuters.com\/world\/china\/china-pledges-support-hong-kong-amid-covid-surge-2022-02-11\/ \"(opens in a new window)\").\n- Germany's chancellor said today that the country is [nearing the peak](https:\/\/www.reuters.com\/world\/europe\/germany-lift-some-restrictions-next-week-covid-peak-sight-2022-02-11\/ \"(opens in a new window)\") of its Omicron surge and that officials will begin lifting some restrictions next week, with an eye toward easing all of them in the spring.\n- Australia's top officials yesterday accepted a recommendation from vaccine advisers that people need to receive booster doses to be considered [fully vaccinated](https:\/\/www.reuters.com\/world\/asia-pacific\/australians-told-get-covid-boosters-be-considered-fully-vaccinated-2022-02-11\/ \"(opens in a new window)\"). However, it will consider international travelers to be fully vaccinated with a two-dose series.\n- The World Health Organization (WHO) today [announced](https:\/\/www.who.int\/news\/item\/11-02-2022-who-prequalifies-first-monoclonal-antibody---tocilizumab-to-treat-covid-19 \"(opens in a new window)\") that it has qualified its first monoclonal antibody, tocilizumab, an intravenous drug designed to inhibit the inflammatory response known to be high in critically ill COVID-19 patients. The drug is already authorized to treat arthritis in about 120 countries. The drug is expensive and supplies are short, but the WHO said more manufacturers are entering the market, with talks under way with Roche about easing access for low- and middle-income countries.\n- The global total today climbed to 407,446,539 cases, and 5,785,805 people have died from their infections, according to the Johns Hopkins [online dashboard](https:\/\/coronavirus.jhu.edu\/ \"(opens in a new window)\").\n\n*CIDRAP News Editor Lisa Schnirring contributed to this story.*\n\n## Related news\nPrevious\n\nNext\n\n[Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds October 8, 2025 Mary Van Beusekom ![Boy in hospital ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/PICU.png?itok=uI6KNOkK)](https:\/\/www.cidrap.umn.edu\/respiratory-syncytial-virus-rsv\/data-pediatric-hospital-strain-amid-2022-23-respiratory-virus)\n\n[CDC announces changes to COVID, childhood vaccines, touting 'informed consent' October 6, 2025 Stephanie Soucheray ![informed patient consent ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/iStock-2190554549.jpg?itok=gb2vMZZz)](https:\/\/www.cidrap.umn.edu\/covid-19\/cdc-announces-changes-covid-childhood-vaccines-touting-informed-consent)\n\n[Nearly 1 in 3 adults with severe long COVID have rare heart-rhythm disorder, data suggest October 6, 2025 Mary Van Beusekom ![Woman with dizziness](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/POTS.png?itok=AW1GqvIY)](https:\/\/www.cidrap.umn.edu\/covid-19\/nearly-1-3-adults-severe-long-covid-have-rare-heart-rhythm-disorder-data-suggest)\n\n[COVID mRNA vaccines may be able to train immune system to attack cancer cells, boost survival October 20, 2025 Mary Van Beusekom ![Doctor pointing to patient's lung x-ray](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/Lung%20cancer.png?itok=Q0HtU345)](https:\/\/www.cidrap.umn.edu\/covid-19\/covid-mrna-vaccines-may-be-able-train-immune-system-attack-cancer-cells-boost-survival)\n\n[Study finds no link between mRNA COVID vaccines early in pregnancy and birth defects October 15, 2025 Mary Van Beusekom ![Mom and infant](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/Infant%20with%20mom.png?itok=E5tPXbU4)](https:\/\/www.cidrap.umn.edu\/covid-19\/study-finds-no-link-between-mrna-covid-vaccines-early-pregnancy-and-birth-defects)\n\n[Report proposes new framework to prepare for future pandemics October 14, 2025 Chris Dall ![Healthcare worker testing for fever](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/iStock-1216924679.jpg?itok=RMnSiz3s)](https:\/\/www.cidrap.umn.edu\/public-health\/report-proposes-new-framework-prepare-future-pandemics)\n\n[Severe COVID may carry higher risk of long-term conditions requiring hospitalization through 6 months October 10, 2025 Mary Van Beusekom ![Woman lying in bed](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/In%20rumpled%20bed.png?itok=34pN1HtY)](https:\/\/www.cidrap.umn.edu\/covid-19\/severe-covid-may-carry-higher-risk-long-term-conditions-requiring-hospitalization-through)\n\n[Data suggest 29% to 64% efficacy of 2024-25 COVID vaccine against poor outcomes in US veterans October 10, 2025 Mary Van Beusekom ![Veteran in the hospital](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/Veteran.png?itok=Gi5JBRHf)](https:\/\/www.cidrap.umn.edu\/covid-19\/data-suggest-29-64-efficacy-2024-25-covid-vaccine-against-poor-outcomes-us-veterans)\n\n[Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds October 8, 2025 Mary Van Beusekom ![Boy in hospital ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/PICU.png?itok=uI6KNOkK)](https:\/\/www.cidrap.umn.edu\/respiratory-syncytial-virus-rsv\/data-pediatric-hospital-strain-amid-2022-23-respiratory-virus)\n\n[CDC announces changes to COVID, childhood vaccines, touting 'informed consent' October 6, 2025 Stephanie Soucheray ![informed patient consent ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/iStock-2190554549.jpg?itok=gb2vMZZz)](https:\/\/www.cidrap.umn.edu\/covid-19\/cdc-announces-changes-covid-childhood-vaccines-touting-informed-consent)\n\n[Nearly 1 in 3 adults with severe long COVID have rare heart-rhythm disorder, data suggest October 6, 2025 Mary Van Beusekom ![Woman with dizziness](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/POTS.png?itok=AW1GqvIY)](https:\/\/www.cidrap.umn.edu\/covid-19\/nearly-1-3-adults-severe-long-covid-have-rare-heart-rhythm-disorder-data-suggest)\n\n[COVID mRNA vaccines may be able to train immune system to attack cancer cells, boost survival October 20, 2025 Mary Van Beusekom ![Doctor pointing to patient's lung x-ray](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/Lung%20cancer.png?itok=Q0HtU345)](https:\/\/www.cidrap.umn.edu\/covid-19\/covid-mrna-vaccines-may-be-able-train-immune-system-attack-cancer-cells-boost-survival)\n\n[Study finds no link between mRNA COVID vaccines early in pregnancy and birth defects October 15, 2025 Mary Van Beusekom ![Mom and infant](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/Infant%20with%20mom.png?itok=E5tPXbU4)](https:\/\/www.cidrap.umn.edu\/covid-19\/study-finds-no-link-between-mrna-covid-vaccines-early-pregnancy-and-birth-defects)\n\n[Report proposes new framework to prepare for future pandemics October 14, 2025 Chris Dall ![Healthcare worker testing for fever](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/iStock-1216924679.jpg?itok=RMnSiz3s)](https:\/\/www.cidrap.umn.edu\/public-health\/report-proposes-new-framework-prepare-future-pandemics)\n\n[Severe COVID may carry higher risk of long-term conditions requiring hospitalization through 6 months October 10, 2025 Mary Van Beusekom ![Woman lying in bed](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/In%20rumpled%20bed.png?itok=34pN1HtY)](https:\/\/www.cidrap.umn.edu\/covid-19\/severe-covid-may-carry-higher-risk-long-term-conditions-requiring-hospitalization-through)\n\n[Data suggest 29% to 64% efficacy of 2024-25 COVID vaccine against poor outcomes in US veterans October 10, 2025 Mary Van Beusekom ![Veteran in the hospital](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/Veteran.png?itok=Gi5JBRHf)](https:\/\/www.cidrap.umn.edu\/covid-19\/data-suggest-29-64-efficacy-2024-25-covid-vaccine-against-poor-outcomes-us-veterans)\n\n[Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds October 8, 2025 Mary Van Beusekom ![Boy in hospital ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/PICU.png?itok=uI6KNOkK)](https:\/\/www.cidrap.umn.edu\/respiratory-syncytial-virus-rsv\/data-pediatric-hospital-strain-amid-2022-23-respiratory-virus)\n\n[CDC announces changes to COVID, childhood vaccines, touting 'informed consent' October 6, 2025 Stephanie Soucheray ![informed patient consent ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/iStock-2190554549.jpg?itok=gb2vMZZz)](https:\/\/www.cidrap.umn.edu\/covid-19\/cdc-announces-changes-covid-childhood-vaccines-touting-informed-consent)\n\n[Nearly 1 in 3 adults with severe long COVID have rare heart-rhythm disorder, data suggest October 6, 2025 Mary Van Beusekom ![Woman with dizziness](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/hand_curated_related_teaser\/public\/article\/POTS.png?itok=AW1GqvIY)](https:\/\/www.cidrap.umn.edu\/covid-19\/nearly-1-3-adults-severe-long-covid-have-rare-heart-rhythm-disorder-data-suggest)\n\n## This week's top reads\n1. [Two new H9N2 avian flu cases reported in China All 21 cases in 2025 have been reported from mainland China. Stephanie Soucheray October 14, 2025](https:\/\/www.cidrap.umn.edu\/avian-influenza-bird-flu\/two-new-h9n2-avian-flu-cases-reported-china)\n2. [Japan sees early flu activity, with school closures Japan typically reports increased influenza activity at the end of November. Stephanie Soucheray October 14, 2025](https:\/\/www.cidrap.umn.edu\/influenza-general\/japan-sees-early-flu-activity-school-closures)\n3. [HEPA purifiers not tied to less viral exposure in elementary classrooms, analysis finds HEPA purifiers were associated with a 33% decrease in viral diversity, but the reduction wasn't linked to fewer school absences. Mary Van Beusekom October 13, 2025 ![HEPA purifier](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/article_teaser\/public\/article\/HEPA%20purifier.png?itok=34LU7yo6)](https:\/\/www.cidrap.umn.edu\/influenza-general\/hepa-purifiers-not-tied-less-viral-exposure-elementary-classrooms-analysis-finds)\n4. [Chaos following mass firings, rehirings at CDC President Trump signaled he would use the government shutdown to lay off \"a lot\" of federal workers. Stephanie Soucheray October 13, 2025 ![cdc building ](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/article_teaser\/public\/article\/iStock-1923650950.jpg?itok=Uw7-vay0)](https:\/\/www.cidrap.umn.edu\/public-health\/chaos-following-mass-firings-rehirings-cdc)\n5. [First locally acquired US case of more severe clade 1 mpox identified in California The clade 1 case is the nation's first in a person with no recent travel history and the seventh clade 1 case in the country. Mary Van Beusekom October 16, 2025 ![Gonorrhea pathogen](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/article_teaser\/public\/article\/Lesions%20on%20hand.png?itok=mH5Biwve)](https:\/\/www.cidrap.umn.edu\/mpox\/first-locally-acquired-us-case-more-severe-clade-1-mpox-identified-california)\n6. [More measles in South Carolina as US nears 1,600 confirmed cases South Carolina officials say all new case-patients were in quarantine before they contracted the disease. Stephanie Soucheray October 15, 2025 ![measles on boy's neck and face](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/article_teaser\/public\/article\/iStock-2152300024_0.jpg?itok=xZuHTvjl)](https:\/\/www.cidrap.umn.edu\/measles\/more-measles-south-carolina-us-nears-1600-confirmed-cases)\n7. [Protection from flu vaccine around 50% for Southern Hemisphere, data reveal Study shows vaccine effectiveness around 50% for both clinic visits and hospital stays for influenza during the 2025 Southern Hemisphere flu season. Jim Wappes October 17, 2025 ![Health worker preparing flu shot](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/styles\/article_teaser\/public\/article\/flu_shot-direct_relief-crop.jpg?itok=tCbhFEjx)](https:\/\/www.cidrap.umn.edu\/influenza-vaccines\/protection-flu-vaccine-around-50-southern-hemisphere-data-reveal)\n8. [Two more measles cases confirmed in Minnesota Last year Minnesota reported 70 measles cases, but 0 in 2023. Stephanie Soucheray October 13, 2025](https:\/\/www.cidrap.umn.edu\/measles\/two-more-measles-cases-confirmed-minnesota)\n9. [US documents dozens of new avian flu cases in wild birds as PAHO notes human case Affected states include Arizona, Illinois, Indiana, Kentucky, Minnesota, Montana, New Hampshire, Oregon, Texas, Utah, West Virginia, Washington, Wisconsin, and Wyoming. Mary Van Beusekom October 16, 2025](https:\/\/www.cidrap.umn.edu\/avian-influenza-bird-flu\/us-documents-dozens-new-avian-flu-cases-wild-birds-paho-notes-human-case)\n10. [Three large turkey farms in Minnesota hit with H5N1 avian flu APHIS also notes several outbreaks in backyard flocks. Stephanie Soucheray October 15, 2025](https:\/\/www.cidrap.umn.edu\/avian-influenza-bird-flu\/three-large-turkey-farms-minnesota-hit-h5n1-avian-flu)\n\n## Our underwriters\n### Unrestricted financial support provided by\n[![Bentson Foundation logo](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/underwriters\/BentsonFound%20Logo%20RGB%200612.jpg) Principal Underwriter](https:\/\/bentsonfoundation.org\/ \"(opens in a new window)\")\n\n[![Unorthodox Philanthropy logo](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/underwriters\/up-4166734.jpeg) Leading Underwriter](https:\/\/www.unorthodoxphilanthropy.org\/ \"(opens in a new window)\")\n\n[![3M Logo](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/underwriters\/3M%20logo.jpg) Major Underwriter](https:\/\/www.3m.com\/ \"(opens in a new window)\")\n\n[![Gilead Logo](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/underwriters\/Gilead.IDtag%202C.pos_.jpg) Supporting Underwriter](https:\/\/www.gilead.com\/ \"(opens in a new window)\")\n\n![Albert Victor Ravenholt Fund](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/underwriters\/avr-logo.png)\n\nSupporting Underwriter\n\n[Become an Underwriter](https:\/\/www.cidrap.umn.edu\/support-cidrap)\n\n![Bordetella pertussis - Maroon](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/2022-08\/bordetella-pertussis-maroon.jpg)\n\n## Help make CIDRAP's vital work possible\n[Support Us](https:\/\/www.cidrap.umn.edu\/support)\n\n- [Home](https:\/\/www.cidrap.umn.edu\/)\n- [Editorial policy](https:\/\/www.cidrap.umn.edu\/editorial-policy)\n- [Search news](https:\/\/www.cidrap.umn.edu\/search)\n\n[![Visit us on Facebook](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/social-icons\/facebook.svg)](https:\/\/www.cidrap.umn.edu\/cidrap-facebook)\n\n[![Twitter](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/social-icons\/twitter_0.svg)](https:\/\/www.cidrap.umn.edu\/cidrap-twitter)\n\n[![Bluesky](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/social-icons\/bluesky.svg)](https:\/\/www.cidrap.umn.edu\/cidrap-bluesky)\n\n[![Youtube](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/social-icons\/youtube.svg)](https:\/\/www.cidrap.umn.edu\/cidrap-youtube)\n\n[![Linkedin](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/social-icons\/linkedin.svg)](https:\/\/www.linkedin.com\/company\/center-for-infectious-disease-research-and-policy-cidrap-?original_referer=https%3A\/\/www.google.com\/ \"(opens in a new window)\")\n\n[![RSS](https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/social-icons\/rss-icon-blue.svg)](https:\/\/www.cidrap.umn.edu\/rss-feeds)\n\n## Contact Us\nCIDRAP - Center for Infectious Disease Research & Policy  \nResearch and Innovation Office, University of Minnesota, Minneapolis, MN\n\n[Email us](https:\/\/www.cidrap.umn.edu\/contact-us \"Contact Us\")\n\n© 2025 Regents of the University of Minnesota. All rights Reserved.  \nThe University of Minnesota is an equal opportunity educator and employer\n\n[Research and Innovation Office](https:\/\/research.umn.edu\/ \"Research and Innovation Office (opens in a new window)\") \\| [Contact U of M](http:\/\/www.umn.edu\/twincities\/contact\/ \"Contact U of M (opens in a new window)\") \\| [Privacy Policy](https:\/\/www.cidrap.umn.edu\/privacy-policy \"Privacy Policy\")\n\n[Newsletter subscribe](https:\/\/www.cidrap.umn.edu\/newsletter)\n\nGet CIDRAP updates\n\n##\nCLOSE\n\n[Close menu](https:\/\/www.cidrap.umn.edu\/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-0)","attrs_readable_markdown":null,"meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

5 months ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	5.9 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial
Last Crawled	2025-10-21 11:39:57 (5 months ago)
First Indexed	2022-12-10 19:34:19 (3 years ago)
HTTP Status Code	200
Meta Title	COVID-19 vaccine for kids under 5 delayed as Pfizer extends trial \| CIDRAP
Meta Description	null
Meta Canonical	null
Boilerpipe Text	In a sudden turnabout, Pfizer and BioNTech today announced they were delaying the application process for an emergency use authorization (EUA) for their vaccine for children ages 6 months to 4 years old, and gathering more information on two and three doses of the vaccine. The announcement comes just days before the Food and Drug Administration (FDA) was set to consider the application, and a day after the Centers for Disease Control and Prevention (CDC) had told pediatric vaccine providers to ready themselves for a Feb 21 delivery date of the mRNA vaccine. "As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial," the FDA said in a statement . "Based on the agency's preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.” In December, Pfizer released data on two 3-microgram doses of the Pfizer-BioNTech vaccine in children 6 months to 4 years. In children 2 years and older, the reduced doses did not elicit a significant immune response, and the company suggested a third dose may be needed. Today in a statement Pfizer said an ongoing study of a third dose of vaccine administered 2 months after the primary series is "advancing at a rapid pace," and the companies will wait for the three-dose data, which they expect to have by early April , before applying for the EUA. The FDA meeting scheduled for Feb 15 has been delayed until further notice. Data: Protection drops 4 months after third dose Today in Morbidity and Mortality Weekly Report, scientists present new research showing that protection against Omicron hospitalizations and emergency department visits drops significantly by 4 months after a third booster dose but is overall still high. Using data from a multistate analysis of 241,204 emergency department encounters and 93,408 hospitalizations for COVID-19 from Aug 26, 2021, to Jan 22, 2022, the authors found vaccine effectiveness (VE) during the Omicron-predominant period was 87% against emergency department or urgent care (ED/UC) visits and 91% against hospitalization during the 2 months following a booster dose of vaccine. VE dropped to 66% and 78% against COVID-19–associated ED/UC visits and hospitalizations, respectively, at 4 months after a booster dose. The authors said the data mirror what has been seen in Israel. The CDC COVID Data Tracker shows that 64.3% of Americans are fully vaccinated against COVID-19, 75.8% have received at least one dose of vaccine, and 42.6% of fully vaccinated Americans have received a booster dose. In related news, the FDA today granted an EUA to bebtelovimab , Eli Lilly's monoclonal antibody, for the treatment of mild to moderate COVID-19 in adults and pediatric patients. Pediatric patients must be at least 12 years of age. Bebtelovimab is effective against infections caused by the Omicron variant, but it must be administered intravenously. Eli Lilly said yesterday that 600,000 courses of the treatment , worth $720 million, have already been made available for the federal government to distribute. Deaths increase in South The United States reported 147,416 new COVID-19 cases yesterday and 3,179 deaths, according to the Johns Hopkins COVID-19 tracker . The 7-day average of new daily cases is 218,688, with 2,613 daily deaths, according to the Washington Post tracker . Two-week COVID-19 death counts have more than doubled in Florida, Hawaii, Mississippi, South Carolina, and Virginia, according to an NBC News analysis of federal data. Twenty-three states have seen a greater than 25% increase in COVID-19 deaths over the past 2 weeks. UK notes rise in subvariant cases Meanwhile, in its latest update on SARS-CoV-2 variants today, the United Kingdom's Health Security Agency (HAS) said the proportion of BA.2 subvariant cases is increasing compared to the original Omicron variant. The rise is occurring against the backdrop of an overall decrease in cases. As of Feb 6, the proportion of BA.2 cases, as indicated by S-gene target positivity on PCR tests, in England is 18.7%, compared with 5.1% Jan 24, which HAS said suggests the growth rate is substantial. Based on limited sequences sampled, there are no confirmed BA.2 reinfections in those infected with the parent Omicron variant. And contact tracing data suggest the average time from symptom onset from a primary case to contacts is about a half day shorter for BA.2 than BA.1, which the HSA said might be contributing to BA.2's increased growth rate. In other global COVID-19 news: Hong Kong again today reported a record high for cases, with 1,323 more reported. Talks are under way with officials in mainland China about ways it could support Hong Kong's overburdened health system during the surge, according to Reuters . Germany's chancellor said today that the country is nearing the peak of its Omicron surge and that officials will begin lifting some restrictions next week, with an eye toward easing all of them in the spring. Australia's top officials yesterday accepted a recommendation from vaccine advisers that people need to receive booster doses to be considered fully vaccinated . However, it will consider international travelers to be fully vaccinated with a two-dose series. The World Health Organization (WHO) today announced that it has qualified its first monoclonal antibody, tocilizumab, an intravenous drug designed to inhibit the inflammatory response known to be high in critically ill COVID-19 patients. The drug is already authorized to treat arthritis in about 120 countries. The drug is expensive and supplies are short, but the WHO said more manufacturers are entering the market, with talks under way with Roche about easing access for low- and middle-income countries. The global total today climbed to 407,446,539 cases, and 5,785,805 people have died from their infections, according to the Johns Hopkins online dashboard . CIDRAP News Editor Lisa Schnirring contributed to this story.
Markdown	Menu - [News](https://www.cidrap.umn.edu/) - [Topics & ProjectsToggle submenu](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-2) - [Antimicrobial Resistance](https://www.cidrap.umn.edu/antimicrobial-stewardship) - [COVID-19](https://www.cidrap.umn.edu/covid-19) - [Chronic Wasting Disease](https://www.cidrap.umn.edu/chronic-wasting-disease) - [Influenza](https://www.cidrap.umn.edu/influenza-general) - [Resilient Drug Supply](https://www.cidrap.umn.edu/resilient-drug-supply) - [Coronavirus Vaccines Roadmap](https://www.cidrap.umn.edu/coronavirus-vaccines-roadmap) - [Influenza Vaccines Roadmap](https://ivr.cidrap.umn.edu/ "(opens in a new window)") - [Roadmaps for Priority Pathogens](https://www.cidrap.umn.edu/roadmap-development) - [Vaccine Integrity Project](https://www.cidrap.umn.edu/vaccine-integrity-project) - [CIDRAP Leadership Forum](https://www.cidrap.umn.edu/forum "CIDRAP Leadership Forum") - . - . - [All Topics A-Z](https://www.cidrap.umn.edu/infectious-disease-topics) - [PodcastsToggle submenu](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-3) - [Antimicrobial Stewardship](https://www.cidrap.umn.edu/antimicrobial-stewardship/superbugs-you) - [Chronic Wasting Disease](https://www.cidrap.umn.edu/chronic-wasting-disease/cwd-pod) - [Osterholm Update](https://www.cidrap.umn.edu/osterholm-update) - [Newsletters](https://www.cidrap.umn.edu/newsletter) - [AboutToggle submenu](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-4) - [About CIDRAP](https://www.cidrap.umn.edu/about-cidrap) - [CIDRAP in the News](https://www.cidrap.umn.edu/cidrap-news) - [Our Staff](https://www.cidrap.umn.edu/about-us/cidrap-staff) - [Our Director](https://www.cidrap.umn.edu/michael-t-osterholdm-phd-mph) - [Osterholm in the Press](https://www.cidrap.umn.edu/osterholm-quotes) - [Shop Merchandise](https://www.mnalumnimarket.com/collections/cidrap?utm_source=website&utm_medium=website&utm_campaign=CIDRAPdonate&utm_content=CIDRAP "(opens in a new window)") - [Contact Us](https://www.cidrap.umn.edu/contact-us) - [Donate](https://www.cidrap.umn.edu/support) [Skip to main content](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#main-content) [Main navigation](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#main-nav) University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 [Go to the U of M home page](http://twin-cities.umn.edu/ "(opens in a new window)") [![Home](https://www.cidrap.umn.edu/themes/custom/cidrap_theme/logo-internal.svg)](https://www.cidrap.umn.edu/ "Home") ## Main navigation - [News](https://www.cidrap.umn.edu/) - - [Antimicrobial Resistance](https://www.cidrap.umn.edu/antimicrobial-stewardship) - [COVID-19](https://www.cidrap.umn.edu/covid-19) - [Chronic Wasting Disease](https://www.cidrap.umn.edu/chronic-wasting-disease) - [Influenza](https://www.cidrap.umn.edu/influenza-general) - [Resilient Drug Supply](https://www.cidrap.umn.edu/resilient-drug-supply) - [All Topics A-Z](https://www.cidrap.umn.edu/infectious-disease-topics) - [Coronavirus Vaccines Roadmap](https://www.cidrap.umn.edu/coronavirus-vaccines-roadmap) - [Influenza Vaccines Roadmap](https://ivr.cidrap.umn.edu/ "(opens in a new window)") - [Roadmaps for Priority Pathogens](https://www.cidrap.umn.edu/roadmap-development) - [Vaccine Integrity Project](https://www.cidrap.umn.edu/vaccine-integrity-project) - [CIDRAP Leadership Forum](https://www.cidrap.umn.edu/forum "CIDRAP Leadership Forum") - . - . Topics & Projects - - [Antimicrobial Stewardship](https://www.cidrap.umn.edu/antimicrobial-stewardship/superbugs-you) - [Chronic Wasting Disease](https://www.cidrap.umn.edu/chronic-wasting-disease/cwd-pod) - [Osterholm Update](https://www.cidrap.umn.edu/osterholm-update) Podcasts - [Newsletters](https://www.cidrap.umn.edu/newsletter) - - [About CIDRAP](https://www.cidrap.umn.edu/about-cidrap) - [CIDRAP in the News](https://www.cidrap.umn.edu/cidrap-news) - [Our Staff](https://www.cidrap.umn.edu/about-us/cidrap-staff) - [Our Director](https://www.cidrap.umn.edu/michael-t-osterholdm-phd-mph) - [Osterholm in the Press](https://www.cidrap.umn.edu/osterholm-quotes) - [Shop Merchandise](https://www.mnalumnimarket.com/collections/cidrap?utm_source=website&utm_medium=website&utm_campaign=CIDRAPdonate&utm_content=CIDRAP "(opens in a new window)") - [Contact Us](https://www.cidrap.umn.edu/contact-us) About Search - [Support](https://www.cidrap.umn.edu/support) [Menu](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#off-canvas "Menu") # COVID-19 vaccine for kids under 5 delayed as Pfizer extends trial Stephanie Soucheray \\| News Reporter \\| CIDRAP News February 11, 2022 [COVID-19](https://www.cidrap.umn.edu/covid-19) ![Pfizer COVID vaccine vial drawing into syringe](https://www.cidrap.umn.edu/sites/default/files/styles/article_detail/public/images/news/pfizer_vax_vial_with_syringe-us_navy.jpg?itok=D-13YH6B) ![Pfizer COVID vaccine vial drawing into syringe](https://www.cidrap.umn.edu/sites/default/files/styles/thumbnail/public/media/article/pfizer_vax_vial_with_syringe-us_navy.jpg?itok=JOb_-X5z) > US Navy, Brett McMinoway / Flickr cc Share In a sudden turnabout, Pfizer and BioNTech today announced they were delaying the application process for an emergency use authorization (EUA) for their vaccine for children ages 6 months to 4 years old, and gathering more information on two and three doses of the vaccine. The announcement comes just days before the Food and Drug Administration (FDA) was set to consider the application, and a day after the Centers for Disease Control and Prevention (CDC) had told pediatric vaccine providers to ready themselves for a Feb 21 delivery date of the mRNA vaccine. "As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial," the FDA said in a [statement](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-postpones-advisory-committee-meeting-discuss-request-authorization "(opens in a new window)"). "Based on the agency's preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.” In December, Pfizer released data on two 3-microgram doses of the Pfizer-BioNTech vaccine in children 6 months to 4 years. In children 2 years and older, the reduced doses did not elicit a significant immune response, and the company suggested a third dose may be needed. Today in a statement Pfizer said an ongoing study of a third dose of vaccine administered 2 months after the primary series is "advancing at a rapid pace," and the companies will wait for the three-dose data, which they [expect to have by early April](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission "(opens in a new window)"), before applying for the EUA. The FDA meeting scheduled for Feb 15 has been delayed until further notice. ### Data: Protection drops 4 months after third dose Today in Morbidity and Mortality Weekly Report, scientists present new research showing that protection against Omicron hospitalizations and emergency department visits drops significantly by 4 months after a third booster dose but is overall still high. [Using data](https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm "(opens in a new window)") from a multistate analysis of 241,204 emergency department encounters and 93,408 hospitalizations for COVID-19 from Aug 26, 2021, to Jan 22, 2022, the authors found vaccine effectiveness (VE) during the Omicron-predominant period was 87% against emergency department or urgent care (ED/UC) visits and 91% against hospitalization during the 2 months following a booster dose of vaccine. VE dropped to 66% and 78% against COVID-19–associated ED/UC visits and hospitalizations, respectively, at 4 months after a booster dose. The authors said the data mirror what has been seen in Israel. The CDC [COVID Data Tracker](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total "(opens in a new window)") shows that 64.3% of Americans are fully vaccinated against COVID-19, 75.8% have received at least one dose of vaccine, and 42.6% of fully vaccinated Americans have received a booster dose. In related news, the FDA today granted an [EUA to bebtelovimab](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains "(opens in a new window)"), Eli Lilly's monoclonal antibody, for the treatment of mild to moderate COVID-19 in adults and pediatric patients. Pediatric patients must be at least 12 years of age. Bebtelovimab is effective against infections caused by the Omicron variant, but it must be administered intravenously. Eli Lilly said yesterday that [600,000 courses of the treatment](https://investor.lilly.com/news-releases/news-release-details/lilly-will-supply-600000-doses-bebtelovimab-us-government "(opens in a new window)"), worth \$720 million, have already been made available for the federal government to distribute. ### Deaths increase in South The United States reported 147,416 new COVID-19 cases yesterday and 3,179 deaths, according to the Johns Hopkins COVID-19 [tracker](https://coronavirus.jhu.edu/data/cumulative-cases "(opens in a new window)"). The 7-day average of new daily cases is 218,688, with 2,613 daily deaths, according to the Washington Post [tracker](https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/?itid=hp_pandemic_gfx/?state=US&indicator=reported_cases "(opens in a new window)"). Two-week COVID-19 death counts have more than doubled in Florida, Hawaii, Mississippi, South Carolina, and Virginia, according to an [NBC News](https://www.nbcnews.com/news/all/covid-death-hot-spot-map-n1288947 "(opens in a new window)") analysis of federal data. Twenty-three states have seen a greater than 25% increase in COVID-19 deaths over the past 2 weeks. ### UK notes rise in subvariant cases Meanwhile, in its latest [update](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054357/Technical-Briefing-36-11February2022_v2.pdf "(opens in a new window)") on SARS-CoV-2 variants today, the United Kingdom's Health Security Agency (HAS) said the proportion of BA.2 subvariant cases is increasing compared to the original Omicron variant. The rise is occurring against the backdrop of an overall decrease in cases. As of Feb 6, the proportion of BA.2 cases, as indicated by S-gene target positivity on PCR tests, in England is 18.7%, compared with 5.1% Jan 24, which HAS said suggests the growth rate is substantial. Based on limited sequences sampled, there are no confirmed BA.2 reinfections in those infected with the parent Omicron variant. And contact tracing data suggest the average time from symptom onset from a primary case to contacts is about a half day shorter for BA.2 than BA.1, which the HSA said might be contributing to BA.2's increased growth rate. In other global COVID-19 news: - Hong Kong again today reported a record high for cases, with [1,323](https://www.info.gov.hk/gia/general/202202/11/P2022021100675.htm?fontSize=1 "(opens in a new window)") more reported. Talks are under way with officials in mainland China about ways it could support Hong Kong's overburdened health system during the surge, according to [Reuters](https://www.reuters.com/world/china/china-pledges-support-hong-kong-amid-covid-surge-2022-02-11/ "(opens in a new window)"). - Germany's chancellor said today that the country is [nearing the peak](https://www.reuters.com/world/europe/germany-lift-some-restrictions-next-week-covid-peak-sight-2022-02-11/ "(opens in a new window)") of its Omicron surge and that officials will begin lifting some restrictions next week, with an eye toward easing all of them in the spring. - Australia's top officials yesterday accepted a recommendation from vaccine advisers that people need to receive booster doses to be considered [fully vaccinated](https://www.reuters.com/world/asia-pacific/australians-told-get-covid-boosters-be-considered-fully-vaccinated-2022-02-11/ "(opens in a new window)"). However, it will consider international travelers to be fully vaccinated with a two-dose series. - The World Health Organization (WHO) today [announced](https://www.who.int/news/item/11-02-2022-who-prequalifies-first-monoclonal-antibody---tocilizumab-to-treat-covid-19 "(opens in a new window)") that it has qualified its first monoclonal antibody, tocilizumab, an intravenous drug designed to inhibit the inflammatory response known to be high in critically ill COVID-19 patients. The drug is already authorized to treat arthritis in about 120 countries. The drug is expensive and supplies are short, but the WHO said more manufacturers are entering the market, with talks under way with Roche about easing access for low- and middle-income countries. - The global total today climbed to 407,446,539 cases, and 5,785,805 people have died from their infections, according to the Johns Hopkins [online dashboard](https://coronavirus.jhu.edu/ "(opens in a new window)"). CIDRAP News Editor Lisa Schnirring contributed to this story. ## Related news Previous Next [Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds October 8, 2025 Mary Van Beusekom ![Boy in hospital ](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/PICU.png?itok=uI6KNOkK)](https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/data-pediatric-hospital-strain-amid-2022-23-respiratory-virus) [CDC announces changes to COVID, childhood vaccines, touting 'informed consent' October 6, 2025 Stephanie Soucheray ![informed patient consent ](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/iStock-2190554549.jpg?itok=gb2vMZZz)](https://www.cidrap.umn.edu/covid-19/cdc-announces-changes-covid-childhood-vaccines-touting-informed-consent) [Nearly 1 in 3 adults with severe long COVID have rare heart-rhythm disorder, data suggest October 6, 2025 Mary Van Beusekom ![Woman with dizziness](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/POTS.png?itok=AW1GqvIY)](https://www.cidrap.umn.edu/covid-19/nearly-1-3-adults-severe-long-covid-have-rare-heart-rhythm-disorder-data-suggest) [COVID mRNA vaccines may be able to train immune system to attack cancer cells, boost survival October 20, 2025 Mary Van Beusekom ![Doctor pointing to patient's lung x-ray](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/Lung%20cancer.png?itok=Q0HtU345)](https://www.cidrap.umn.edu/covid-19/covid-mrna-vaccines-may-be-able-train-immune-system-attack-cancer-cells-boost-survival) [Study finds no link between mRNA COVID vaccines early in pregnancy and birth defects October 15, 2025 Mary Van Beusekom ![Mom and infant](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/Infant%20with%20mom.png?itok=E5tPXbU4)](https://www.cidrap.umn.edu/covid-19/study-finds-no-link-between-mrna-covid-vaccines-early-pregnancy-and-birth-defects) [Report proposes new framework to prepare for future pandemics October 14, 2025 Chris Dall ![Healthcare worker testing for fever](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/iStock-1216924679.jpg?itok=RMnSiz3s)](https://www.cidrap.umn.edu/public-health/report-proposes-new-framework-prepare-future-pandemics) [Severe COVID may carry higher risk of long-term conditions requiring hospitalization through 6 months October 10, 2025 Mary Van Beusekom ![Woman lying in bed](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/In%20rumpled%20bed.png?itok=34pN1HtY)](https://www.cidrap.umn.edu/covid-19/severe-covid-may-carry-higher-risk-long-term-conditions-requiring-hospitalization-through) [Data suggest 29% to 64% efficacy of 2024-25 COVID vaccine against poor outcomes in US veterans October 10, 2025 Mary Van Beusekom ![Veteran in the hospital](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/Veteran.png?itok=Gi5JBRHf)](https://www.cidrap.umn.edu/covid-19/data-suggest-29-64-efficacy-2024-25-covid-vaccine-against-poor-outcomes-us-veterans) [Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds October 8, 2025 Mary Van Beusekom ![Boy in hospital ](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/PICU.png?itok=uI6KNOkK)](https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/data-pediatric-hospital-strain-amid-2022-23-respiratory-virus) [CDC announces changes to COVID, childhood vaccines, touting 'informed consent' October 6, 2025 Stephanie Soucheray ![informed patient consent ](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/iStock-2190554549.jpg?itok=gb2vMZZz)](https://www.cidrap.umn.edu/covid-19/cdc-announces-changes-covid-childhood-vaccines-touting-informed-consent) [Nearly 1 in 3 adults with severe long COVID have rare heart-rhythm disorder, data suggest October 6, 2025 Mary Van Beusekom ![Woman with dizziness](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/POTS.png?itok=AW1GqvIY)](https://www.cidrap.umn.edu/covid-19/nearly-1-3-adults-severe-long-covid-have-rare-heart-rhythm-disorder-data-suggest) [COVID mRNA vaccines may be able to train immune system to attack cancer cells, boost survival October 20, 2025 Mary Van Beusekom ![Doctor pointing to patient's lung x-ray](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/Lung%20cancer.png?itok=Q0HtU345)](https://www.cidrap.umn.edu/covid-19/covid-mrna-vaccines-may-be-able-train-immune-system-attack-cancer-cells-boost-survival) [Study finds no link between mRNA COVID vaccines early in pregnancy and birth defects October 15, 2025 Mary Van Beusekom ![Mom and infant](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/Infant%20with%20mom.png?itok=E5tPXbU4)](https://www.cidrap.umn.edu/covid-19/study-finds-no-link-between-mrna-covid-vaccines-early-pregnancy-and-birth-defects) [Report proposes new framework to prepare for future pandemics October 14, 2025 Chris Dall ![Healthcare worker testing for fever](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/iStock-1216924679.jpg?itok=RMnSiz3s)](https://www.cidrap.umn.edu/public-health/report-proposes-new-framework-prepare-future-pandemics) [Severe COVID may carry higher risk of long-term conditions requiring hospitalization through 6 months October 10, 2025 Mary Van Beusekom ![Woman lying in bed](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/In%20rumpled%20bed.png?itok=34pN1HtY)](https://www.cidrap.umn.edu/covid-19/severe-covid-may-carry-higher-risk-long-term-conditions-requiring-hospitalization-through) [Data suggest 29% to 64% efficacy of 2024-25 COVID vaccine against poor outcomes in US veterans October 10, 2025 Mary Van Beusekom ![Veteran in the hospital](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/Veteran.png?itok=Gi5JBRHf)](https://www.cidrap.umn.edu/covid-19/data-suggest-29-64-efficacy-2024-25-covid-vaccine-against-poor-outcomes-us-veterans) [Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds October 8, 2025 Mary Van Beusekom ![Boy in hospital ](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/PICU.png?itok=uI6KNOkK)](https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/data-pediatric-hospital-strain-amid-2022-23-respiratory-virus) [CDC announces changes to COVID, childhood vaccines, touting 'informed consent' October 6, 2025 Stephanie Soucheray ![informed patient consent ](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/iStock-2190554549.jpg?itok=gb2vMZZz)](https://www.cidrap.umn.edu/covid-19/cdc-announces-changes-covid-childhood-vaccines-touting-informed-consent) [Nearly 1 in 3 adults with severe long COVID have rare heart-rhythm disorder, data suggest October 6, 2025 Mary Van Beusekom ![Woman with dizziness](https://www.cidrap.umn.edu/sites/default/files/styles/hand_curated_related_teaser/public/article/POTS.png?itok=AW1GqvIY)](https://www.cidrap.umn.edu/covid-19/nearly-1-3-adults-severe-long-covid-have-rare-heart-rhythm-disorder-data-suggest) ## This week's top reads 1. [Two new H9N2 avian flu cases reported in China All 21 cases in 2025 have been reported from mainland China. Stephanie Soucheray October 14, 2025](https://www.cidrap.umn.edu/avian-influenza-bird-flu/two-new-h9n2-avian-flu-cases-reported-china) 2. [Japan sees early flu activity, with school closures Japan typically reports increased influenza activity at the end of November. Stephanie Soucheray October 14, 2025](https://www.cidrap.umn.edu/influenza-general/japan-sees-early-flu-activity-school-closures) 3. [HEPA purifiers not tied to less viral exposure in elementary classrooms, analysis finds HEPA purifiers were associated with a 33% decrease in viral diversity, but the reduction wasn't linked to fewer school absences. Mary Van Beusekom October 13, 2025 ![HEPA purifier](https://www.cidrap.umn.edu/sites/default/files/styles/article_teaser/public/article/HEPA%20purifier.png?itok=34LU7yo6)](https://www.cidrap.umn.edu/influenza-general/hepa-purifiers-not-tied-less-viral-exposure-elementary-classrooms-analysis-finds) 4. [Chaos following mass firings, rehirings at CDC President Trump signaled he would use the government shutdown to lay off "a lot" of federal workers. Stephanie Soucheray October 13, 2025 ![cdc building ](https://www.cidrap.umn.edu/sites/default/files/styles/article_teaser/public/article/iStock-1923650950.jpg?itok=Uw7-vay0)](https://www.cidrap.umn.edu/public-health/chaos-following-mass-firings-rehirings-cdc) 5. [First locally acquired US case of more severe clade 1 mpox identified in California The clade 1 case is the nation's first in a person with no recent travel history and the seventh clade 1 case in the country. Mary Van Beusekom October 16, 2025 ![Gonorrhea pathogen](https://www.cidrap.umn.edu/sites/default/files/styles/article_teaser/public/article/Lesions%20on%20hand.png?itok=mH5Biwve)](https://www.cidrap.umn.edu/mpox/first-locally-acquired-us-case-more-severe-clade-1-mpox-identified-california) 6. [More measles in South Carolina as US nears 1,600 confirmed cases South Carolina officials say all new case-patients were in quarantine before they contracted the disease. Stephanie Soucheray October 15, 2025 ![measles on boy's neck and face](https://www.cidrap.umn.edu/sites/default/files/styles/article_teaser/public/article/iStock-2152300024_0.jpg?itok=xZuHTvjl)](https://www.cidrap.umn.edu/measles/more-measles-south-carolina-us-nears-1600-confirmed-cases) 7. [Protection from flu vaccine around 50% for Southern Hemisphere, data reveal Study shows vaccine effectiveness around 50% for both clinic visits and hospital stays for influenza during the 2025 Southern Hemisphere flu season. Jim Wappes October 17, 2025 ![Health worker preparing flu shot](https://www.cidrap.umn.edu/sites/default/files/styles/article_teaser/public/article/flu_shot-direct_relief-crop.jpg?itok=tCbhFEjx)](https://www.cidrap.umn.edu/influenza-vaccines/protection-flu-vaccine-around-50-southern-hemisphere-data-reveal) 8. [Two more measles cases confirmed in Minnesota Last year Minnesota reported 70 measles cases, but 0 in 2023. Stephanie Soucheray October 13, 2025](https://www.cidrap.umn.edu/measles/two-more-measles-cases-confirmed-minnesota) 9. [US documents dozens of new avian flu cases in wild birds as PAHO notes human case Affected states include Arizona, Illinois, Indiana, Kentucky, Minnesota, Montana, New Hampshire, Oregon, Texas, Utah, West Virginia, Washington, Wisconsin, and Wyoming. Mary Van Beusekom October 16, 2025](https://www.cidrap.umn.edu/avian-influenza-bird-flu/us-documents-dozens-new-avian-flu-cases-wild-birds-paho-notes-human-case) 10. [Three large turkey farms in Minnesota hit with H5N1 avian flu APHIS also notes several outbreaks in backyard flocks. Stephanie Soucheray October 15, 2025](https://www.cidrap.umn.edu/avian-influenza-bird-flu/three-large-turkey-farms-minnesota-hit-h5n1-avian-flu) ## Our underwriters ### Unrestricted financial support provided by [![Bentson Foundation logo](https://www.cidrap.umn.edu/sites/default/files/underwriters/BentsonFound%20Logo%20RGB%200612.jpg) Principal Underwriter](https://bentsonfoundation.org/ "(opens in a new window)") [![Unorthodox Philanthropy logo](https://www.cidrap.umn.edu/sites/default/files/underwriters/up-4166734.jpeg) Leading Underwriter](https://www.unorthodoxphilanthropy.org/ "(opens in a new window)") [![3M Logo](https://www.cidrap.umn.edu/sites/default/files/underwriters/3M%20logo.jpg) Major Underwriter](https://www.3m.com/ "(opens in a new window)") [![Gilead Logo](https://www.cidrap.umn.edu/sites/default/files/underwriters/Gilead.IDtag%202C.pos_.jpg) Supporting Underwriter](https://www.gilead.com/ "(opens in a new window)") ![Albert Victor Ravenholt Fund](https://www.cidrap.umn.edu/sites/default/files/underwriters/avr-logo.png) Supporting Underwriter [Become an Underwriter](https://www.cidrap.umn.edu/support-cidrap) ![Bordetella pertussis - Maroon](https://www.cidrap.umn.edu/sites/default/files/2022-08/bordetella-pertussis-maroon.jpg) ## Help make CIDRAP's vital work possible [Support Us](https://www.cidrap.umn.edu/support) - [Home](https://www.cidrap.umn.edu/) - [Editorial policy](https://www.cidrap.umn.edu/editorial-policy) - [Search news](https://www.cidrap.umn.edu/search) [![Visit us on Facebook](https://www.cidrap.umn.edu/sites/default/files/social-icons/facebook.svg)](https://www.cidrap.umn.edu/cidrap-facebook) [![Twitter](https://www.cidrap.umn.edu/sites/default/files/social-icons/twitter_0.svg)](https://www.cidrap.umn.edu/cidrap-twitter) [![Bluesky](https://www.cidrap.umn.edu/sites/default/files/social-icons/bluesky.svg)](https://www.cidrap.umn.edu/cidrap-bluesky) [![Youtube](https://www.cidrap.umn.edu/sites/default/files/social-icons/youtube.svg)](https://www.cidrap.umn.edu/cidrap-youtube) [![Linkedin](https://www.cidrap.umn.edu/sites/default/files/social-icons/linkedin.svg)](https://www.linkedin.com/company/center-for-infectious-disease-research-and-policy-cidrap-?original_referer=https%3A//www.google.com/ "(opens in a new window)") [![RSS](https://www.cidrap.umn.edu/sites/default/files/social-icons/rss-icon-blue.svg)](https://www.cidrap.umn.edu/rss-feeds) ## Contact Us CIDRAP - Center for Infectious Disease Research & Policy Research and Innovation Office, University of Minnesota, Minneapolis, MN [Email us](https://www.cidrap.umn.edu/contact-us "Contact Us") © 2025 Regents of the University of Minnesota. All rights Reserved. The University of Minnesota is an equal opportunity educator and employer [Research and Innovation Office](https://research.umn.edu/ "Research and Innovation Office (opens in a new window)") \\| [Contact U of M](http://www.umn.edu/twincities/contact/ "Contact U of M (opens in a new window)") \\| [Privacy Policy](https://www.cidrap.umn.edu/privacy-policy "Privacy Policy") [Newsletter subscribe](https://www.cidrap.umn.edu/newsletter) Get CIDRAP updates ## CLOSE [Close menu](https://www.cidrap.umn.edu/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial#mm-0)
Readable Markdown	null
Shard	45 (laksa)
Root Hash	1624480930799954845
Unparsed URL	edu,umn!cidrap,www,/covid-19-vaccine-kids-under-5-delayed-pfizer-extends-trial s443